We recently published our article 5 Best Cheap AI Medicine Stocks to Buy Now. To read the full article, head on to 10 Best Cheap AI Medicine Stocks to Buy Now. In this piece, we take a closer look at GE HealthCare Technologies Inc. (NASDAQ:GEHC) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

5 Best Cheap AI Medicine Stocks to Buy Now

1. GE HealthCare Technologies Inc. (NASDAQ:GEHC)

GE HealthCare Technologies Inc. (NASDAQ: GEHC) earns the No. 1 position as the strongest overall combination of valuation, profitability, financial stability and real-world artificial intelligence adoption.

The company operates across medical imaging, ultrasound, patient monitoring and pharmaceutical diagnostics. Its equipment is already installed in hospitals and clinics around the world, creating a direct distribution channel for new AI-enabled healthcare products.

This installed base is a major advantage. A startup may develop an impressive medical algorithm but struggle to convince hospitals to change their systems. The company can integrate artificial intelligence into equipment and workflows that healthcare professionals already understand and use.

Its AI applications can help improve image quality, automate measurements, prioritize urgent cases and reduce the amount of time clinicians spend performing repetitive tasks. The company has also consistently ranked among the manufacturers with the largest number of FDA-listed AI-enabled medical-device authorizations. This demonstrates that its AI strategy has progressed beyond laboratory research and into regulated clinical products.

Second-quarter 2026 revenue increased 5.7%, while organic revenue grew 3.5%. Organic orders climbed a record 11.1%, producing a book-to-bill ratio of 1.15. Backlog reached $23.9 billion, providing substantial visibility into future demand. Net income margin was 10.6%, while diluted EPS increased 16.5% to $1.24. The official second-quarter report provides the complete financial results and guidance.

At approximately $68.86 per share, the stock traded at around 15.8 times trailing earnings. That is a considerably more reasonable valuation than those of many medical-device and artificial intelligence companies. Investors receive exposure to AI-powered diagnostics without depending on a single experimental treatment or an uncertain biotechnology financing cycle.

The tradeoff is that a large and established company is less likely to produce the sudden 10-fold gains possible in a successful micro-cap biotechnology stock. Nevertheless, it also carries a much lower probability of complete failure.

For investors searching for cheap AI medicine stocks to buy now, this represents the most credible risk-adjusted opportunity. Its growing order book, global customer base, profitable operations and leadership in AI-enabled medical technology give it several paths to create long-term shareholder value.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.